Open AccessFEATURES OF CYTOKINE PROFILE IN PATIENTS WITH DIFFERENT TYPES OF MULTIPLE SCLEROSIS
Author(s) -
N Vdovichenko,
Oleh Koliada,
O. V. Tupotilov
Publication year - 2020
Publication title -
ìmunologìâ ta alergologìâ: nauka ì praktika
Language(s) - English
Resource type - Journals
ISSN - 2707-1871
DOI - 10.37321/immunology.2020.01-02
Subject(s) - multiple sclerosis , expanded disability status scale , medicine , cytokine , gastroenterology , correlation , positive correlation , stage (stratigraphy) , negative correlation , disease , progressive disease , immunology , biology , paleontology , geometry , mathematics
Purpose of the study In order to determine the serum levels of cytokines of patients in Kharkov and Kharkov region with relapsing-remitting and progressive types of multiple sclerosis (MS) at different periods of disease activity, as well as to establish a relationship between the state of the regulatory immunity, progression of MS and the degree of EDSS (Expanded Disability Status Scale) of patients, 98 patients with MS, as well as 27 healthy individuals, were examined.
Material and methods. To determine the content of serum cytokines we used the method of enzyme-linked immunosorbent assay. An elevated levels of IFN-g, IL-1b and IL-12 were revealed in groups with RRMS. At the same time, in the group of patients with RRMS at the stage of clinical and radiological remission, increased production of IL-1b and IL-12 was accompanied by a compensatory increasing of IL-10 level.
The results. An imbalance of cytokines was observed in patients with progressive MS. Regardless of the stage of progression an increased levels of IL-1b, IL-12 and IFN-g were observed, more expressed in patients with progressive MS than in patients with relapsing-remitting MS. Аt the same time, the level of IL-10 was reduced. The presence of a correlation between the EDSS and the level of IL-1b (r = 0.349, p = 0.031) and a negative correlation between the rate of disability and the level of IL-10 (r = -0.4371, p = 0.0414) were detected in patients with progressive types of MS at the stage of steady progression.
Conclusions. Therefore, the determination of clinical and laboratory markers of the MS activity is of great importance for predicting the activity of the disease, the alternative of further treatment tactics and monitoring the effectiveness of pathogenetic therapy.